The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR‐ABL‐negative myeloproliferative neoplasm …
H Baccouche, M Ben Jemaa… - International Journal …, 2017 - Wiley Online Library
H Baccouche, M Ben Jemaa, A Chakroun, S Chadi, S Mahjoub, I Sfar, Y Gorgi…
International Journal of Laboratory Hematology, 2017•Wiley Online LibraryIntroduction It has been recently suggested that microparticles (MP) play a role in the
pathogenesis of thrombotic complications. This study aimed to assess the contribution of
procoagulant activity expressed by circulating MP in thrombotic events in MPN patients.
Methods Seventy‐four MPN patients were enrolled in a trans‐sectional study. The MP
procoagulant activity was measured using two assays:(i) the thrombin generation (TG) assay
used in different conditions with the addition of both tissue factor (TF) and phospholipids …
pathogenesis of thrombotic complications. This study aimed to assess the contribution of
procoagulant activity expressed by circulating MP in thrombotic events in MPN patients.
Methods Seventy‐four MPN patients were enrolled in a trans‐sectional study. The MP
procoagulant activity was measured using two assays:(i) the thrombin generation (TG) assay
used in different conditions with the addition of both tissue factor (TF) and phospholipids …
Introduction
It has been recently suggested that microparticles (MP) play a role in the pathogenesis of thrombotic complications. This study aimed to assess the contribution of procoagulant activity expressed by circulating MP in thrombotic events in MPN patients.
Methods
Seventy‐four MPN patients were enrolled in a trans‐sectional study. The MP procoagulant activity was measured using two assays: (i) the thrombin generation (TG) assay used in different conditions with the addition of both tissue factor (TF) and phospholipids (PL) and with the addition of TF or PL alone and (ii) the PROCOAG‐PPL assay.
Results
The mean age was 62 (26 men and 48 women). The prevalence of thrombotic events was 28%. When comparing patients with thrombosis to those without, age, sex, MPN type, cardiovascular risk factors, and history of thrombosis were not significantly associated with thrombosis. The JAK2 V617F mutation was significantly associated with thrombotic events (90% vs 67%; P=.04). Results from the TG assay and the PROCOAG‐PPL assays did not demonstrate a significant association between the MP procoagulant activity and thrombotic events.
Conclusion
The MP procoagulant activity did not predict thrombosis in MPN patients. The contribution of TG assay in the assessment of the thrombotic risk is still in debate.
Wiley Online Library